Editor-in-Chief (EIC)(Dr. Cory L. Brooks) and Deputy EIC (Dr. Andrei Moroz) of Monoclonal
Antibodies in Immunodiagnosis and Immunotherapy. We inherit a legacy of rigorous …

Highlights•Multiple companies are authorized to treat COVID-19 patients with monoclonal
antibodies (mAbs).•They were discovered, developed, manufactured, tested, and approved …

Background: With the number of Coronavirus Disease 2019 (COVID-19) cases on the rise
around the world, monoclonal antibodies (mAb) remain a feasible treatment option for …

Throughout history, pandemics like the Black Death or the Spanish Flue have periodically
wiped out large parts of populations. Today, history repeats itself with the on-going SARS …

This article is made available for historical review, monoclonal antibody use is not currently
indicated for this condition. COVID-19 illness is a clinical syndrome caused by a SARS-CoV …

The COVID-19 pandemic has reminded us that no country is immune to the threat posed by
emerging infectious diseases. Ensuring prompt, affordable, and equitable global access to …

The COVID-19 pandemic continues to cause tremendous loss of life and put massive strain
on the functioning of societies worldwide. Despite the cataclysmic proportions of this viral …

6. Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab
for COVID-19. Available from: https://www. biocon. com/biocon-presented-insights-into …

Monoclonal antibodies (mAbs) have emerged as potent therapeutic agents, revolutionizing
the landscape of modern medicine. This comprehensive review traces the evolution of mAbs …

Of all the scientific research focused on addressing the novel coronavirus pandemic, much
involves vaccine development. Most public health experts agree that an effective, globally …